Neither work in any appreciable way, in fact, both
Post# of 147858
(Total Views: 561)
Posted On: 01/07/2021 2:40:41 PM
Neither work in any appreciable way, in fact, both effectively shut down the immune system and allow for secondary infections (highly likely) as well as liver complication and malignancies.
https://www.covid19treatmentguidelines.nih.go...nhibitors/
The UK is taking a page from the US and just approving anything to try to keep the sheep calm. Disgusting.
https://www.covid19treatmentguidelines.nih.go...nhibitors/
Quote:
Recommendation
The Panel recommends against the use of anti-IL-6 receptor monoclonal antibodies (e.g., sarilumab, tocilizumab) or anti-IL-6 monoclonal antibody (siltuximab) for the treatment of COVID-19, except in a clinical trial (BI).
Rationale
Preliminary, unpublished data from randomized, controlled trials failed to demonstrate efficacy of sarilumab or tocilizumab in patients with COVID-19. There are only limited, unpublished data describing the efficacy of siltuximab in patients with COVID-19.11
The UK is taking a page from the US and just approving anything to try to keep the sheep calm. Disgusting.
Quote:
The UK government is working closely with the manufacturer, to ensure the drugs - tocilizumab and sarilumab - continue to be available to UK patients.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼